AC Immune (ACIU) to Release Earnings on Monday

AC Immune (NASDAQ:ACIU) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect AC Immune to post earnings of ($0.22) per share and revenue of $0.32 million for the quarter.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The company had revenue of $1.12 million during the quarter, compared to analysts’ expectations of $1.99 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $1.67 on Friday. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.98. The firm has a market capitalization of $167.68 million, a price-to-earnings ratio of -3.63 and a beta of 1.62. The business’s 50 day simple moving average is $1.84 and its 200-day simple moving average is $2.52.

Analysts Set New Price Targets

Several research firms have recently issued reports on ACIU. StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. HC Wainwright reduced their price target on shares of AC Immune from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 1st.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.